{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:59:30Z","timestamp":1793336370034,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJQN202200446"],"award-info":[{"award-number":["KJQN202200446"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001869"],"award-info":[{"award-number":["82001869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22371026"],"award-info":[{"award-number":["22371026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.118000","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T10:27:05Z","timestamp":1754389625000},"page":"118000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["trans-Styrylquinazolinone CYP1B1 inhibitors as potential therapeutics in A549 cells"],"prefix":"10.1016","volume":"298","author":[{"given":"Jiajing","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1834-0308","authenticated-orcid":false,"given":"Dachuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118000_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrc2015","article-title":"The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis","volume":"6","author":"Nebert","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118000_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2018.11.039","article-title":"Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1","volume":"163","author":"Mohd Siddique","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1177\/1087057116675315","article-title":"Development of an in vitro model to screen CYP1B1-Targeted anticancer prodrugs","volume":"21","author":"Wang","year":"2016","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ejmech.2025.118000_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129112","article-title":"A new class of CYP1B1 inhibitors derived from bentranil","volume":"80","author":"Yi","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118000_bib5","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/cmdc.201600316","article-title":"Flavonoids and naphthoflavonoids: wider roles in the modulation of cytochrome P450 family 1 enzymes","volume":"11","author":"Dong","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118000_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/dmd.119.086892","article-title":"Nitidine chloride-induced CYP1 enzyme inhibition and alteration of estradiol metabolism","volume":"47","author":"Mao","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2025.118000_bib7","article-title":"Discovery of CYP1A1 inhibitors for host-directed therapy against sepsis","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111938","article-title":"Synthesis and structure-activity relationship studies of \u03b1-naphthoflavone derivatives as CYP1B1 inhibitors","volume":"187","author":"Dong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/1871520623666230119103914","article-title":"P. CYP1B1: a promising target in cancer drug discovery","volume":"23","author":"Fabris","year":"2023","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/carcin\/bgp252","article-title":"Basic properties and molecular mechanisms of exogenous chemical carcinogens","volume":"31","author":"Irigaray","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2025.118000_bib11","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1021\/acs.jmedchem.4c00164","article-title":"Design of novel 2-Phenylquinazolin-4-amines as selective CYP1B1 inhibitors for overcoming paclitaxel resistance in A549 cells","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib12","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.1021\/acs.jmedchem.2c01306","article-title":"Structure-based drug design and synthesis of novel N-Aryl-2,4-bithiazole-2-amine CYP1B1-Selective inhibitors in overcoming taxol resistance in A549 cells","volume":"65","author":"Mao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3892\/ijmm.2014.2041","article-title":"CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro","volume":"35","author":"Zhu","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118000_bib14","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.bmcl.2017.11.013","article-title":"Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme","volume":"27","author":"Sharma","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118000_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1039\/C6MD00394J","article-title":"Adaptive mechanisms of resistance to anti-neoplastic agents","volume":"8","author":"Ferreira","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2025.118000_bib16","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1042\/CS20200310","article-title":"CYP1B1 as a therapeutic target in cardio-oncology","volume":"134","author":"Carrera","year":"2020","journal-title":"Clin. Sci. (Lond)."},{"key":"10.1016\/j.ejmech.2025.118000_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112028","article-title":"Design and synthesis of \u03b1-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation","volume":"189","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib18","doi-asserted-by":"crossref","first-page":"10901","DOI":"10.1021\/acs.jmedchem.8b01633","article-title":"Design, synthesis, and biological evaluation of cytochrome P450 1B1 targeted molecular imaging probes for colorectal tumor detection","volume":"61","author":"Meng","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129533","article-title":"Design, synthesis, and evaluation of (18)F-Labeling CYP1B1 PET tracer based on 2-Phenylquinazolin","volume":"96","author":"Cai","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118000_bib20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118000_bib21","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/tx980090+","article-title":"Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1","volume":"11","author":"Shimada","year":"1998","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118000_bib22","first-page":"8164","article-title":"A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis","volume":"61","author":"Chun","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118000_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/tx2004163","article-title":"Inhibition of cytochrome p450 enzymes by quinones and anthraquinones","volume":"25","author":"Sridhar","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118000_bib24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.taap.2013.07.005","article-title":"Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling","volume":"272","author":"Lo","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118000_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.dmpk.2015.08.006","article-title":"Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites","volume":"30","author":"Chang","year":"2015","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118000_bib26","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1021\/acs.jmedchem.5b00265","article-title":"Design and synthesis of new \u03b1-Naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression","volume":"58","author":"Cui","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2174\/09298673113206660277","article-title":"Inhibitors and prodrugs targeting CYP1: a novel approach in cancer prevention and therapy","volume":"21","author":"Cui","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib28","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1039\/C6OB01506A","article-title":"Biphenyl urea derivatives as selective CYP1B1 inhibitors","volume":"14","author":"Mohd Siddique","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmech.2017.02.032","article-title":"Quinazoline derivatives as selective CYP1B1 inhibitors","volume":"130","author":"Mohd Siddique","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115552","article-title":"Discovery of 4'-trifluoromethylchalcones as novel, potent and selective hCYP1B1 inhibitors without concomitant AhR activation","volume":"258","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib31","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1016\/j.tetlet.2018.09.014","article-title":"Bismuth-catalyzed synthesis of 2-Substituted quinazolinones","volume":"59","author":"Vemula","year":"2018","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118000_bib32","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1080\/00397911.2017.1315672","article-title":"Suzuki\u2013miyaura coupling of quinazolines containing an unprotected NH2 group: synthesis and biological testing of quinazoline derivatives","volume":"47","author":"Pulipati","year":"2017","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2025.118000_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.ejmech.2025.118000_bib34","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/cancers13184705","article-title":"Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy","volume":"13","author":"Rodak","year":"2021","journal-title":"Cancers. (Basel)."},{"key":"10.1016\/j.ejmech.2025.118000_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial","volume":"32","author":"Shi","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118000_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116670","article-title":"Ferroptosis-inducing compounds synergize with docetaxel to overcome chemoresistance in docetaxel-resistant non-small cell lung cancer cells","volume":"276","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113733","article-title":"Overcoming Taxol-resistance in A549 cells: a comprehensive strategy of targeting P-gp transporter, AKT\/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin","volume":"171","author":"Lin","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118000_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tiv.2009.12.002","article-title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism","volume":"24","author":"Zordoky","year":"2010","journal-title":"Toxicol. In. Vitro"},{"key":"10.1016\/j.ejmech.2025.118000_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4236\/ojmc.2014.41002","article-title":"Utility of 2-Methyl-quinazolin-4(3H)-one in the synthesis of heterocyclic compounds with anticancer activity","volume":"4","author":"Helali","year":"2014","journal-title":"Open. Journal. of. Medicinal. Chemistry."},{"key":"10.1016\/j.ejmech.2025.118000_bib40","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1016\/j.bmc.2006.08.030","article-title":"Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs","volume":"14","author":"Al-Rashood","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bmcl.2008.12.076","article-title":"Development of thioquinazolinones, allosteric Chk1 kinase inhibitors","volume":"19","author":"Converso","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118000_bib42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejmech.2003.12.009","article-title":"Synthesis, cytotoxicity and inhibitory effect on tubulin polymerization of 3-Heterocyclosubstituted 2-Styrylquina-zolinone","volume":"39","author":"Raffa","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154672","article-title":"Molecular biology of microRNA-342 during tumor progression and invasion","volume":"248","author":"Taghehchian","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2025.118000_bib44","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1530\/EC-19-0225","article-title":"Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk","volume":"8","author":"Rizzolo","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ejmech.2025.118000_bib45","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.3390\/cancers15215284","article-title":"Exploring cell migration mechanisms in cancer: from wound healing assays to cellular automata models","volume":"15","author":"Migliaccio","year":"2023","journal-title":"Cancers. (Basel)."},{"key":"10.1016\/j.ejmech.2025.118000_bib46","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1021\/ci4003156","article-title":"Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor","volume":"53","author":"Chen","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118000_bib47","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.bmc.2010.02.025","article-title":"Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones","volume":"18","author":"Mrozek-Wilczkiewicz","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111710","article-title":"Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases","volume":"184","author":"Baska","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bmc.2008.11.012","article-title":"Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists","volume":"17","author":"Okano","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117193","article-title":"Discovery of fluorinated 2-Styryl 4(3H)-quinazolinone as potential therapeutic hit for oral cancer","volume":"81","author":"Parshuram Satpute","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib51","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1021\/acscatal.6b00728","article-title":"Merging C\u2013H Bond Functionalization with Amide Alcoholysis: en Route to 2-Aminopyridines","volume":"6","author":"Kumar","year":"2016","journal-title":"ACS Catal."},{"key":"10.1016\/j.ejmech.2025.118000_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111851","article-title":"2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation and in vivo effective anticancer agents","volume":"186","author":"Wei","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib53","first-page":"1","article-title":"Preparation and herbicidal properties of ring-substituted 4-Chloro-2-styrylquinazolines","author":"Polanski","year":"2011","journal-title":"Syn. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118000_bib54","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated modeling program, applied chemical theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:13:10Z","timestamp":1772788390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"alternative-id":["S0223523425007652"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118000","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"trans-Styrylquinazolinone CYP1B1 inhibitors as potential therapeutics in A549 cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118000"}}